Nuclear hexokinase 2 couples hyperglycemia to MYC-driven glycolytic and stemness programs in bladder cancer

van Hoogstraten LMC, Vrieling A, van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol. 2023;20:287–304.

Google Scholar 

Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, et al. Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol. 2022;5:628–39.

Google Scholar 

Xiao K, Peng S, Lu J, Zhou T, Hong X, Chen S, et al. UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer. Cell Death Dis. 2023;14:408.

Google Scholar 

Wu J, Huang M, Dong W, Chen Y, Zhou Q, Zhang Q, et al. SUMO E3 ligase MUL1 inhibits lymph node metastasis of bladder cancer by mediating mitochondrial HSPA9 translocation. Int J Biol Sci. 2024;20:3986–4006.

Google Scholar 

He Y, Chen Y, Gao C. A Mendelian randomization study on the association between type 2 diabetes and the risk of bladder cancer. Discov Oncol. 2025;16:446.

Google Scholar 

Gill E, Sandhu G, Ward DG, Perks CM, Bryan RT. The sirenic links between diabetes, obesity, and bladder cancer. Int J Mol Sci 2021;22.

Barba I, Carrillo-Bosch L, Seoane J. Targeting the Warburg effect in cancer: Where do we stand? Int J Mol Sci. 2024;25.

Tufail M, Jiang CH, Li N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol Cancer. 2024;23:203.

Google Scholar 

Yang Z, Zheng Y, Gao Q. Lysine lactylation in the regulation of tumor biology. Trends Endocrinol Metab. 2024;35:720–31.

Google Scholar 

Qian Y, Zhu X, Niu D, Tang Q, Jin C. Advancements in research on the role of the key glycolytic enzyme hexokinase 2 in the regulation of tumor immune evasion (Review). Oncol Lett. 2025;30:593.

Google Scholar 

He K, Tao F, Lu Y, Fang M, Huang H, Zhou Y. The role of HK2 in tumorigenesis and development: potential for targeted therapy with natural products. Int J Med Sci. 2025;22:790–805.

Google Scholar 

Afonso J, Goncalves C, Costa M, Ferreira D, Santos L, Longatto-Filho A, et al. Glucose metabolism reprogramming in bladder cancer: hexokinase 2 (HK2) as prognostic biomarker and target for bladder cancer therapy. Cancers. 2023;15.

Lee SH, Golinska M, Griffiths JR. HIF-1-independent mechanisms regulating metabolic adaptation in hypoxic cancer cells. Cells. 2021;10.

Wan W, Peng K, Li M, Qin L, Tong Z, Yan J, et al. Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1alpha. Oncogene. 2017;36:3868–77.

Google Scholar 

Zhang C, Liu J, Xu D, Zhang T, Hu W, Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 2020;12:674–87.

Google Scholar 

Yu Q, Dai W, Ji J, Wu L, Feng J, Li J, et al. Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c-myc/hexokinase 2 pathway. J Cell Mol Med. 2022;26:3031–45.

Google Scholar 

Xu D, Shao F, Bian X, Meng Y, Liang T, Lu Z. The Evolving Landscape of Noncanonical Functions of Metabolic Enzymes in Cancer and Other Pathologies. Cell Metab. 2021;33:33–50.

Google Scholar 

Snaebjornsson MT, Schulze A. Non-canonical functions of enzymes facilitate cross-talk between cell metabolic and regulatory pathways. Exp Mol Med. 2018;50:1–16.

Google Scholar 

Guo D, Tong Y, Jiang X, Meng Y, Jiang H, Du L, et al. Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IkappaBalpha. Cell Metab. 2022;34:1312–24.e1316.

Google Scholar 

Duan Y, Liu Z, Wang Q, Zhang J, Liu J, Zhang Z, et al. Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology. Genes Dis. 2025;12:101435.

Google Scholar 

Li M, Yu J, Ju L, Wang Y, Jin W, Zhang R, et al. USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer. Cell Death Dis. 2024;15:44.

Google Scholar 

Chhipa AS, Patel S. Targeting pyruvate kinase muscle isoform 2 (PKM2) in cancer: What do we know so far? Life Sci. 2021;280:119694.

Google Scholar 

David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2010;463:364–8.

Google Scholar 

Li Y, Zhang S, Li Y, Liu J, Li Q, Zang W, et al. The regulatory network of hnRNPs underlying regulating PKM alternative splicing in tumor progression. Biomolecules 2024,14.

Das B, Pal B, Bhuyan R, Li H, Sarma A, Gayan S, et al. MYC regulates the HIF2alpha stemness pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells. Cancer Res. 2019;79:4015–25.

Google Scholar 

Zhang Z, Zhang Y. Transcriptional regulation of cancer stem cell: regulatory factors elucidation and cancer treatment strategies. J Exp Clin Cancer Res. 2024;43:99.

Google Scholar 

Li X, Egervari G, Wang Y, Berger SL, Lu Z. Regulation of chromatin and gene expression by metabolic enzymes and metabolites. Nat Rev Mol Cell Biol. 2018;19:563–78.

Google Scholar 

Zhang J, Ouyang F, Gao A, Zeng T, Li M, Li H, et al. ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent Warburg effect within the hypoxic tumor microenvironment. Mol Cancer. 2024;23:94.

Google Scholar 

Yang W, Lu Z. Pyruvate kinase M2 at a glance. J Cell Sci. 2015;128:1655–60.

Google Scholar 

Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci USA. 2013;110:1303–8.

Google Scholar 

Thomas GE, Egan G, Garcia-Prat L, Botham A, Voisin V, Patel PS, et al. The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness. Nat Cell Biol. 2022;24:872–84.

Google Scholar 

Zhan H, Wang H, Pan B, Lu J, Xiao K, Lai J, et al. Reprogramming the tumor microenvironment with c-MYC-based gene circuit platform to enhance specific cancer immunotherapy. Nat Commun. 2025;16:7983.

Google Scholar 

Zhang C, Liu S, Zhang J, Lu J, Chen Z, Pan B, et al. A multifunctional Fe-EGCG@RSL3 nanomedicine synergizes ferroptosis induction and tumor microenvironment remodeling for enhanced bladder cancer immunotherapy. Research. 2025;8:0735.

Google Scholar 

Wang H, Zhan H, Pan B, Zeng L, Chen Z, Liu S, et al. Engineering CRISPR system-based bacterial outer membrane vesicle potentiates T cell immunity for enhanced cancer immunotherapy. Adv Mater. 2025;37:e2501565.

Google Scholar 

Nath K, Guo L, Nancolas B, Nelson DS, Shestov AA, Lee SC, et al. Mechanism of antineoplastic activity of lonidamine. Biochim Biophys Acta. 2016;1866:151–62.

Google Scholar 

Zhu H, Jia Z, Li YR, Danelisen I. Molecular mechanisms of action of metformin: latest advances and therapeutic implications. Clin Exp Med. 2023;23:2941–51.

Google Scholar 

Liu S, Wang X, Sun X, Wei B, Jiang Z, Ouyang Y, et al. Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1. Phytomedicine. 2024;126:155426.

Google Scholar 

Tong Y, Guo D, Lin SH, Liang J, Yang D, Ma C, et al. SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumor cells. Mol Cell. 2021;81:2303–16.e2308.

Google Scholar 

Liu R, Lee JH, Li J, Yu R, Tan L, Xia Y, et al. Choline kinase alpha 2 acts as a protein kinase to promote lipolysis of lipid droplets. Mol Cell. 2021;81:2722–35.e2729.

Google Scholar